Streetwise Articles



Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate
Source: Streetwise Reports  (1/16/19)
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated. More >


Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data
Source: Streetwise Reports  (1/11/19)
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report. More >


Healthcare Solutions Provider to Acquire Medical Software Firm
Source: Streetwise Reports  (1/10/19)
The merger will allow the Canadian company to expand its online technology platform. More >


Target Raised on Nutraceutical Firm After It Inks 'Marquee Partnership'
Source: Streetwise Reports  (1/9/19)
The agreement terms and benefits of the partnership to this pharmaceutical company were relayed in an H.C. Wainwright & Co. report. More >


Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic
Source: Streetwise Reports  (1/5/19)
The background and justification for the deal was covered in an H.C. Wainwright & Co. report. More >


Potential Tenbagger Biopharma Displays 'Strong Start to New Year'
Source: Streetwise Reports  (1/4/19)
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock. More >


Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset
Source: Streetwise Reports  (1/2/19)
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production. More >


Coverage Initiated on Pharma 'Leveraging Large Markets with Differentiated Products'
Source: Streetwise Reports  (12/29/18)
A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm. More >


Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning
Source: Streetwise Reports  (12/24/18)
An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH. More >


Coverage Initiated on Vaccine Developer with 'Transformational' Data Expected
Source: Streetwise Reports  (12/24/18)
A Ladenburg Thalmann report discussed this biotech's late-stage clinical assets in RSV and influenza. More >


Analyst: Biopharma Makes 'Right Call' in Stopping Combination Agent in Trial
Source: Streetwise Reports  (12/19/18)
A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study. More >


Urgent Update on Canadian Health Company Acquisition
Source: Clive Maund for Streetwise Reports  (12/18/18)
Technical analyst Clive Maund charts the potentially transformative acquisition of a medical software provider in Canada. More >


Frederick Lacy

15 Reasons Why Hemp Producer Elixinol Should Be in Your Portfolio
Source: Fincom Investment Partners for Streetwise Reports  (12/17/18)
With the U.S. government legalizing hemp in the recently passed 2018 Farm Bill, Fincom Investment Partners profiles a hemp company whose largest market is the U.S. More >


Ron Struthers

Small-Cap Firm Announces Major Medical Technology Acquisition
Source: Ron Struthers for Streetwise Reports  (12/17/18)
Ron Struthers of Struthers Resource Stock Report profiles an innovative medical firm in Canada that just announced the acquisition of a medical technology firm, a move that will expand its reach across Canada. More >


Telehealth Services Provider's Positive Q3/18 Results Reflect 'Robust Growth Rate'
Source: Streetwise Reports  (12/12/18)
A William Blair report reviewed the firm's operational and financial numbers for the period. More >


Coverage Initiated on Tech Firm Servicing Healthcare Industry
Source: Streetwise Reports  (12/12/18)
Haywood Securities presented the thesis for investment in this company, including its growth drivers and continued focus on acquisition. More >


Strong Health Stock 'Ready to Commence New Upleg'
Source: Clive Maund for Streetwise Reports  (12/11/18)
Technical analyst Clive Maund analyzes a rapidly expanding company with medical clinics in British Columbia that is using advanced technology and AI. More >


Health Stock 'Looking Set to Bounce Back After 90% Drop'
Source: Clive Maund for Streetwise Reports  (12/11/18)
Technical analyst Clive Maund charts a telemedicine technology company and explains why he believes the company's stock should rebound. More >


Small-Cap Company Could Be the Face of the Future of Medicine
Source: Streetwise Reports  (12/10/18)
A company in Canada that is changing the paradigm for providing healthcare in Canada and potentially elsewhere by integrating technology and artificial intelligence has just announced a major acquisition. More >


Biotech Delivers Positive Study Results for Prostate Cancer Prognostic Test
Source: Streetwise Reports  (12/5/18)
An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application. More >


Precision Medicine Developer Secures Another Patent for Drug Candidate
Source: Streetwise Reports  (12/5/18)
This company takes a step forward in its efforts to protect its intellectual property. More >


Biotech to Lead dMAB Tech Field with First Clinically Tested Product
Source: Streetwise Reports  (11/28/18)
An H.C. Wainwright & Co. report discussed recent articles covering results of this firm's preclinical studies. More >


Neuromonitoring Stock 'Ready to Rally'
Source: Clive Maund for Streetwise Reports  (11/26/18)
Technical analyst Clive Maund charts a neuromonitoring company that he believes is undervalued. More >


Cannabis Provider to Debut Five More Dispensaries in Florida
Source: Streetwise Reports  (11/26/18)
This company plans to add even more this year as well. More >


Biopharma Agrees to $215 Million Acquisition Deal
Source: Streetwise Reports  (11/21/18)
An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger. More >


Showing Results: 1 to 25 of 996 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts